Market research and consulting firm Frost & Sullivan said on Tuesday that it has awarded ZAGENO, a procurement orchestration platform for life sciences, its 2026 North America Life Sciences E-Commerce Company of the Year Recognition for helping transform life sciences e-commerce beyond traditional online purchasing into a unified procurement orchestration platform.
By serving as a single entry point into scientific procurement, ZAGENO enables scientists, procurement teams, suppliers, and enterprise systems to operate within one connected workflow, reducing procurement friction while improving governance, visibility, and operational efficiency across research organisations.
"We're honoured to receive this recognition from Frost & Sullivan," commented Florian Wegener, CEO and co-founder of ZAGENO. "As research organisations become more connected and more complex, procurement has evolved far beyond purchasing. Our vision has always been to simplify that complexity by bringing scientists, procurement teams, suppliers, and enterprise systems together through a single procurement orchestration platform. We're proud to see that vision recognised, and even more excited about what's ahead for our customers."
Each year, Frost & Sullivan honours one company with its Company of the Year Recognition for organisations that demonstrate exceptional growth, innovation, and customer value. The selection process includes rigorous research, competitive benchmarking, and in-depth industry analysis.
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Orphalan commences Phase 3 study of trientine therapy in Wilson disease
ZAGENO named Frost & Sullivan's 2026 North American Life Sciences E-Commerce Company of the Year
Pharvaris reports Phase 3 success for deucrictibant XR in HAE prophylaxis
Sky Labs presents clinical research outcomes for ring-type blood pressure monitor CART
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer
4basebio announces expansion of DNA offering for personalised mRNA medicines
Rznomics reports advances in high-efficiency circRNA production in Nucleic Acids Research
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease